PT - JOURNAL ARTICLE AU - Paturi, Vishnupriya R. AU - Uppuluri, Ramakrishna R. AU - Gao, Lina AU - Roberts, Charles T. AU - Nagalla, Srinivasa R. TI - ANTI-CITRULLINATED ALBUMIN ANTIBODIES AS BIOMARKER FOR THE DIAGNOSIS OF RHEUMATOID ARTHRITIS AID - 10.1101/2023.08.04.23292887 DP - 2023 Jan 01 TA - medRxiv PG - 2023.08.04.23292887 4099 - http://medrxiv.org/content/early/2023/08/10/2023.08.04.23292887.short 4100 - http://medrxiv.org/content/early/2023/08/10/2023.08.04.23292887.full AB - Objective Citrullinated human serum albumin has been previously reported in serum and synovial fluid from individuals with rheumatoid arthritis (RA), and antibodies to citrullinated human serum albumin (ACA) have been identified in RA serum. We developed a point-of-care (POC) test for ACA and evaluated its sensitivity and specificity in healthy subjects and subjects with clinically diagnosed RA and other rheumatic conditions and autoimmune disease.Methods The POC test is a lateral-flow immunoassay using antihuman IgA/G/M and anti-human serum albumin antibodies for detection of citrullinated serum albumin-ACA complexes. This test was used to determine serum or plasma ACA levels in a South Asian study population comprised of healthy controls (n=484) and subjects with clinically diagnosed RA (n=354) or other rheumatic (n=103) and autoimmune diseases (n=60), and compared to the levels of rheumatoid factor (RF) and anticitrullinated cyclic peptide antibodies (ACPA).Results Sensitivity of ACA for RA was 0.520 and specificity was 0.994. ACA prevalence in other rheumatoid disease was similar to that of ACPA and less than that of RF. ACA was detected in 12% of RA samples that were negative for ACPA. The combined sensitivity of ACA+ACPA was 0.664 and the combined specificity was 0.845.Conclusion The ACA POC test exhibits robust sensitivity and specificity for RA diagnosis in serum or plasma and, in conjunction with ACPA, can enable rapid and efficient differential diagnosis of RA with increased sensitivity and comparable specificity.Competing Interest StatementVRP and SRN are employees of, and CTR is a shareholder in, Diabetomics, Inc., which funded this study.Funding StatementThis study was funded by Diabetomics, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval for this study was obtained from the Sri Deepti Rheumatology Center, Hyderabad, Telangana, India, IRB, and the study was registered with regulatory authorities (CTRI/2020/10/028596), and informed consent was obtained from all study participants.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript.